

| Market Applicability |    |          |        |        |    |    |    |    |    |    |    |    |    |    |    |
|----------------------|----|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Market               | DC | FL & FHK | FL MMA | FL LTC | GA | KS | KY | LA | MD | NJ | NV | NY | TN | TX | WA |
| Applicable           | X  | X        | NA     | NA     | X  | NA | X  | X  | X  | X  | X  | X  | NA | NA | X  |

\*FHK- Florida Healthy Kids

# Vancomycin

| Override(s)         | Approval Duration |
|---------------------|-------------------|
| Prior Authorization | 1 year            |

| Medications   |
|---|
| Vancocin (vancomycin) oral capsules<br>Firvanq (vancomycin) oral suspension |

## APPROVAL CRITERIA

Requests for brand or generic oral Vancocin (vancomycin) or Firvanq (vancomycin) may be approved for individuals who meet the following criteria:

- I. Individual is being treated for enterocolitis caused by *Staphylococcus aureus* (including methicillin-resistant strains);

**OR**

- II. Individual is being treated for *Clostridium difficile*-associated diarrhea; **AND**
  - A. Individual has had a trial and inadequate response or intolerance to or has a contraindication to oral metronidazole for mild-moderate *Clostridium difficile* infection (IDSA 2010); **OR**
  - B. Individual is being treated for a severe or severe, complicated *Clostridium difficile* infection (IDSA 2010); **OR**
  - C. Individual is pregnant, intending to become pregnant, or is breastfeeding (Surawicz 2013); **OR**
  - D. Individual is being treated for relapsed or recurrent *Clostridium difficile*-associated diarrhea (IDSA 2010).

| State Specific Mandates |                |   |
|-------------------------|----------------|---|
| State name              | Date effective | Mandate details (including specific bill if applicable) |
| N/A                     | N/A            | N/A   |

### Key References:

Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2017.  
URL: <http://www.clinicalpharmacology.com>. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

| Market Applicability |    |          |        |        |    |    |    |    |    |    |    |    |    |    |    |
|----------------------|----|----------|--------|--------|----|----|----|----|----|----|----|----|----|----|----|
| Market               | DC | FL & FHK | FL MMA | FL LTC | GA | KS | KY | LA | MD | NJ | NV | NY | TN | TX | WA |
| Applicable           | X  | X        | NA     | NA     | X  | NA | X  | X  | X  | X  | X  | X  | NA | NA | X  |

\*FHK- Florida Healthy Kids

Cohen SH, Gerding DN, Johnson S, et al. Clinical Practice Guidelines for *Clostridium difficile* Infection in Adults: 2010 Update by the Society for Healthcare Epidemiology of America (SHEA) and the Infectious Diseases Society of America (IDSA). *Infect Control Hosp Epidemiol.* 2010;31:431-455.

DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: July 5, 2017.

DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. *Clin Infect Dis.* 2016;63(5):e61-111.

Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2017; Updated periodically.

Liu C, Bayer A, Cosgrove SE, et. al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant *Staphylococcus aureus* infections in adults and children. *Clin Infect Dis.* 2011 Feb 1;52(3):e18-55. doi: 10.1093/cid/ciq146. Epub 2011 Jan 4.

Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. *Clin Infect Dis.* 2014 Jul 15;59(2):e10-52. doi: 10.1093/cid/ciu296. Epub 2014 Jun 18.

Surawicz CM, Brandt LJ, Binion DG, Ananthakrishnan AN, Curry SR, Gilligan PH, McFarland LV, Mellow M, Zuckerbraun BS. Guidelines for diagnosis, treatment, and prevention of *Clostridium difficile* infections. *Am J Gastroenterol.* 2013 Apr;108(4):478-98.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.